FDA accepts iclaprim NDA

FDA accepted for review an NDA from Arpida (SWX:ARPN) for IV iclaprim to treat complicated skin and skin structure infections (cSSSIs). The PDUFA date is Jan. 16, 2009. The broad-spectrum antibiotic t...